Etira founder Dr. Jung-Mo Ahn highlighted in local press

Dallas, Texas. October 31, 2022. We are pleased to share two news articles from Dallas that describe how our brilliant chemist and founder, Dr. Jung-Mo Ahn discovered ERX-41. In his words, Dr. Ahn describes the discovery of ERX-41 as “It’s almost like two elephants are hugging each other, and you’re throwing a pebble to stop them.”

The articles can be accessed here: https://www.dallasnews.com/news/2022/10/31/dallas-researchers-create-molecule-that-kills-hard-to-treat-cancers/

https://dallasinnovates.com/the-last-word-ut-dallas-dr-jung%E2%80%91mo-ahn-on-creating-a-new-cancer-fighting-molecule/

About Etira
EtiraRx is a privately owned Dallas-based biotech startup focused on developing the next generation of cancer therapies. EtiraRx is advancing their first small molecule drug, ERX-315, to phase I clinical trials later this year for patients with metastatic breast cancer.

Learn more at www.etiraRx.com
contact@etirarx.com